<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213575</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201500594 -N</org_study_id>
    <secondary_id>RO1HL3361028</secondary_id>
    <secondary_id>2013-00102 Study 3</secondary_id>
    <secondary_id>R01HL132448</secondary_id>
    <nct_id>NCT02213575</nct_id>
  </id_info>
  <brief_title>Study 3: Minocycline Decreases Microglia Activation</brief_title>
  <official_title>Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a mechanistic study that will enroll 9 subjects who are participating in&#xD;
      NCT02133885 (which is designed to evaluate minocycline to test the hypothesis that&#xD;
      minocycline treatment would produce antihypertensive effects in drug-resistant neurogenic&#xD;
      hypertensive individuals) to test whether the antihypertensive effect of minocycline is&#xD;
      associated with a decrease in activated microglia in central nervous system autonomic regions&#xD;
      as evidenced by changes in PET and MRI imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will recruit 9 subjects from NCT02133885 who will agree to undergo additional&#xD;
      autonomic testing and imaging studies at baseline and after 3-6 months of study treatment.&#xD;
      Specialized imaging of the brain using magnetic resonance imaging (MRI) and positron emission&#xD;
      tomography (PET) scanning will be conducted at the Montreal Neurological Institute, in&#xD;
      Montreal Canada.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2022</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI changes in the paraventricular nucleus</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>MRI changes in the paraventricular nucleus from baseline to 12 weeks. Increased binding in the autonomic brain regions (paraventricular nucleus)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI changes in the paraventricular nucleus</measure>
    <time_frame>Change in Baseline to 24 weeks</time_frame>
    <description>MRI changes in the paraventricular nucleus from baseline to 24 weeks. Increased binding in the autonomic brain regions (paraventricular nucleus)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PET changes in the paraventricular nucleus</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>PET changes in the paraventricular nucleus from baseline to 12 weeks. Increased binding in the autonomic brain regions (paraventricular nucleus)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PET changes in the paraventricular nucleus</measure>
    <time_frame>Change in Baseline to 24 weeks</time_frame>
    <description>PET changes in the paraventricular nucleus from baseline to 24 weeks. Increased binding in the autonomic brain regions (paraventricular nucleus)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.</description>
    <arm_group_label>Minocycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects participating in IRB approved protocol #102-2013 will be eligible to&#xD;
             participate.&#xD;
&#xD;
          -  (For Study 3 Participants only) Willing to travel to Montreal, Canada for specialized&#xD;
             imaging of the participant's brain using magnetic resonance imaging (MRI), positron&#xD;
             emission tomography (PET) scanning, Autonomic Nervous System Testing and blood&#xD;
             drawing- if participant qualifies&#xD;
&#xD;
        Exclusion criteria for control and resistant hypertensive subjects include:&#xD;
&#xD;
          -  currently pregnant or have been pregnant in the last 6 months;&#xD;
&#xD;
          -  antibiotic treatment within 2 months of study enrollment;&#xD;
&#xD;
          -  currently taking a medication (e.g., antibiotic, anti-inflammatory agents,&#xD;
             glucocorticoids or other immune modulating medications);&#xD;
&#xD;
          -  unwilling to discontinue vitamin or supplements, including probiotics, potentially&#xD;
             affecting gut microbiota (vitamins/supplements and medications that possibly affect&#xD;
             the gut microbiota should be discontinued for at least 2wks prior to stool&#xD;
             collection);&#xD;
&#xD;
          -  history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose&#xD;
             intolerance, chronic pancreatitis or other malabsorption disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Pepine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Leach, DNP</last_name>
    <phone>352-273-8933</phone>
    <email>leachdd@medicine.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Long, RN</last_name>
    <phone>352-273-8933</phone>
    <email>sarah.long@medicine.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UF Health Cardiovascular Clinic</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistent Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

